These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 23871661

  • 21. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
    Hermesse J, Biver S, Jansen N, Lenaerts E, Nickers P.
    Int J Radiat Oncol Biol Phys; 2010 Jan 01; 76(1):269-76. PubMed ID: 19775833
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
    Chen WC, Li Y, Lazar A, Altun A, Descovich M, Nano T, Ziemer B, Sudhyadhom A, Cunha A, Thomas H, Gottschalk A, Hsu IC, Roach M.
    Int J Radiat Oncol Biol Phys; 2021 Jun 01; 110(2):429-437. PubMed ID: 33385496
    [Abstract] [Full Text] [Related]

  • 24. Outcomes of Asian patients with localized prostate cancer treated with combined intensity modulated radiation therapy (IMRT) and high dose rate (HDR) brachytherapy: A single institution experience.
    Ng IWS, Tey JCS, Soon YY, Tseng MSF, Chen D, Lim KHC.
    Asia Pac J Clin Oncol; 2018 Oct 01; 14(5):e386-e391. PubMed ID: 29171166
    [Abstract] [Full Text] [Related]

  • 25. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy.
    Kestin LL, Goldstein NS, Vicini FA, Mitchell C, Gustafson GS, Stromberg JS, Chen PY, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2002 Sep 01; 54(1):107-18. PubMed ID: 12182980
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
    King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, Lee LJ, Mouw KW, Martin NM, D'Amico AV, Nguyen PL, Orio PF.
    Brachytherapy; 2019 Sep 01; 18(2):186-191. PubMed ID: 30638912
    [Abstract] [Full Text] [Related]

  • 28. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
    Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D.
    J Urol; 2016 May 01; 195(5):1453-1458. PubMed ID: 26576709
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
    Pellizzon AC, Salvajoli J, Novaes P, Maia M, Fogaroli R, Gides D, Horriot R.
    Int J Med Sci; 2008 Jun 04; 5(3):113-20. PubMed ID: 18566673
    [Abstract] [Full Text] [Related]

  • 31. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
    Falk AT, Demontoy S, Chamorey E, Chand ME, Gautier M, Azria D, Zaki S, Chevallier D, Cham Kee DL, Hannoun-Lévi JM.
    Brachytherapy; 2017 Jun 04; 16(5):993-999. PubMed ID: 28754301
    [Abstract] [Full Text] [Related]

  • 32. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer.
    Kestin LL, Martinez AA, Stromberg JS, Edmundson GK, Gustafson GS, Brabbins DS, Chen PY, Vicini FA.
    J Clin Oncol; 2000 Aug 04; 18(15):2869-80. PubMed ID: 10920135
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
    Spratt DE, Zumsteg ZS, Ghadjar P, Kollmeier MA, Pei X, Cohen G, Polkinghorn W, Yamada Y, Zelefsky MJ.
    BJU Int; 2014 Sep 04; 114(3):360-7. PubMed ID: 24447404
    [Abstract] [Full Text] [Related]

  • 35. Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-front Radical Radiation Therapy for Prostate Cancer.
    Berlin A, Ahmad AE, Chua MLK, Moraes FY, Jiang H, Komisarenko M, Trimilshina N, Raziee H, Hosni A, Murgic J, Chung P, Bristow RG, Finelli A.
    Int J Radiat Oncol Biol Phys; 2018 Mar 01; 100(3):702-709. PubMed ID: 29249526
    [Abstract] [Full Text] [Related]

  • 36. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.